🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 63 Shanghai 52 Guangzhou 40 Hangzhou 19 Fuzhou 19
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines10 LaNova Medicines Limited3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences3 Suzhou Zelgen Biopharmaceuticals Co.,Ltd2 MediLink Therapeutics (Suzhou) Co., Ltd.2
Site location
Beijing63 Shanghai52 Guangzhou40 Hangzhou19 Fuzhou19
All 68 locations
Target enrolment
to

Trials with a site in Beijing

63 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors
NCT07811037Advanced Solid Tumor
Beijing Sungen Biomedical Technology Co., Ltd
Phase 1/2
332
Beijing
2026-08-17
Recruiting
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
NCT07669415Advanced Solid Tumor
LaNova Medicines Limited
Phase 2
108
Beijing
2026-07-29
Recruiting
Evaluation of ICP-B208 in Patients With Advanced Solid Tumors
NCT07617493Advanced Solid Tumor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
539
Beijing
2026-07-03
Recruiting
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
NCT07512583Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
178
Beijing, Harbin, Tianjin
2026-05-27
Recruiting
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
NCT07414836Advanced Solid Tumor
BeOne Medicines
Phase 1
84
Beijing, Chongqing, Fuzhou, Guangzhou, Yichang, Shanghai
2026-04-13
Recruiting
A Study of MG2512 Injection in Participants With Advanced Solid Tumors
NCT07348653Advanced Solid Tumor
Shanghai Mabgen Biopharmaceutical Technology Co., Ltd.
Phase 1
116
Beijing, Chengdu
2026-03-18
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
YSCH-01 Via Nebulization in Pulmonary Metastasis of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC)
NCT07793500NSCLC, Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
36
Beijing
2025-11-27
Recruiting
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
NCT07181681Solid Tumors, Advanced Solid Tumor
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Not yet open
Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
NCT07142837Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
153
Beijing
2025-09
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348Advanced Solid Tumor
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.
NCT06173219Advanced Solid Tumor
China-Japan Friendship Hospital
Phase 1/2
38
Beijing
2025-08-01
Recruiting
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
NCT07083323Advanced Solid Tumor
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1/2
262
Beijing
2025-07-22
Recruiting
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06953323Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
Recruiting
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin
2025-07-02
Recruiting
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
NCT06992713Advanced Solid Tumor
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Phase 1
36
Nanjing, Beijing, Shanghai
2025-06-18
Not yet open
Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation
NCT06970132Advanced Solid Tumor
Shouyao Holdings (Beijing) Co. LTD
Phase 1/2
102
Beijing
2025-06
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Not yet open
A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours
NCT06873854Advanced Solid Tumor
LaNova Medicines Limited
Phase 2
84
Beijing
2025-03-26
Recruiting
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
NCT06803680Advanced Solid Tumor, Metastatic Solid Tumor
BeOne Medicines
Phase 1
90
Beijing, Nanchang, Shanghai, Taiyuan
2025-03-18
Recruiting
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
NCT06589596Advanced Solid Tumor
BeOne Medicines
Phase 1
525
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Meizhou, Nanning
2025-01-10
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
NCT06772415Advanced Solid Tumor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Recruiting
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
NCT06625593Advanced Solid Tumor
BeOne Medicines
Phase 1
168
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Nanning, Shijiazhuang, Harbin
2024-12-09
Recruiting
A Study of ES014 in Subjects With Advanced Solid Tumors
NCT06543056Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
15
Beijing
2024-11-25
Recruiting
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
NCT06959615Advanced Solid Tumor
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
NCT06598800Advanced Solid Tumor
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Recruiting
Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
NCT06484985Non-Hodgkin Lymphoma, Advanced Solid Tumor
Axter Therapeutics (Beijing) Co., Ltd
Phase 1
78
Beijing, Changsha, Fuzhou, Guangzhou, Shanghai
2024-09-04
Recruiting
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
NCT06512116Advanced Solid Tumor
Shanghai Institute Of Biological Products
Phase 1
196
Beijing
2024-07-23
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
420
Beijing, Guangzhou, Shanghai
2024-07-01
Not yet open
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
NCT06446388Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.
Phase 2
360
Beijing
2024-06-30
Recruiting
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
NCT06233942Advanced Solid Tumor
BeOne Medicines
Phase 1
308
Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Dalian, Shenyang, Jinan
2024-04-12
Active, closed
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06328673Advanced Solid Tumor
D2M Biotherapeutics Inc.
Phase 1
160
Beijing
2024-04-09
Recruiting
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
NCT06257680Advanced Solid Tumor
Beijing Xunsheng Biomedical Research Co., Ltd.
Phase 1
15
Beijing
2024-04-08
Recruiting
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
NCT06240546Advanced Solid Tumor
Luye Pharma Group Ltd.
Phase 1
102
Beijing
2024-03-12
Active, closed
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
NCT06238479Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
490
Beijing, Changsha, Shanghai
2024-03-05
Active, closed
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
NCT06244485Advanced Solid Tumor
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Recruiting
Study SC-101 in Subjects With Advanced Malignancies
NCT06220838Advanced Solid Tumor
Tianjin ConjuStar Biologics Co., Ltd.
Phase 1
100
Beijing, Changsha, Nanjing, Shanghai, Tianjin
2024-02-02
Not yet open
A Study of Simmitinib Plus SG001 in Advanced Solid Tumors
NCT06132217Advanced Solid Tumor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase 1/2
168
Beijing
2024-01-30
Recruiting
Clinical Trial of BT02 in Patients With Advanced Solid Tumors
NCT06404905Advanced Solid Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
60
Beijing
2024-01-24
Recruiting
MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors
NCT06170294Advanced Solid Tumor
Peking University
Phase 1
20
Beijing
2024-01-01
Recruiting
A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors
NCT06211647Advanced Solid Tumor
Ruimin Wang
Phase 1
20
Beijing
2024-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Active, closed
A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors
NCT06143007Advanced Solid Tumor
Broadenbio Ltd., Co.
Phase 1
42
Beijing
2023-10-26
Active, closed
A Study YL201 in Patients With Selected Advanced Solid Tumors
NCT06057922Advanced Solid Tumor
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Beijing, Jinan, Neijiang, Shanghai
2023-08-18
Recruiting
A Study of BA1202 in Patients With Advanced Solid Tumors
NCT05909241Advanced Solid Tumor
Shandong Boan Biotechnology Co., Ltd
Phase 1
78
Beijing
2023-08-16
Recruiting
A Study of EOC237 in Patients With Advanced Solid Tumor
NCT05895825Advanced Solid Tumor
Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd
Phase 1
48
Beijing
2023-07-26
Active, closed
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
NCT05700084Advanced Solid Tumor
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 1/2
84
Beijing, Chengdu, Guangzhou, Jinan, Shanghai, Shenyang, Shijiazhuang, Wuhan
2023-06-09
Recruiting
A Study of BPI-460372 in Advanced Solid Tumor Patients
NCT05789602Advanced Solid Tumor
Betta Pharmaceuticals Co., Ltd.
Phase 1
82
Beijing, Baoding, Harbin, Wuhan, Changsha, Changchun, Jinan, Taizhou
2023-04-24
Not yet open
A Study of KM602 in Patients With Advanced Solid Tumors
NCT05766527Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
38
Beijing
2023-04
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Ha’erbin, Hefei, Jinan
2023-03-15
Recruiting
Study of ZGGS18 in Patients With Advanced Solid Tumors
NCT05584800Advanced Solid Tumor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
222
Beijing
2022-11-15
Active, closed
A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors
NCT05518045Advanced Solid Tumor
LaNova Medicines Limited
Phase 1/2
392
Beijing
2022-08-26
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
NCT05487170Advanced Solid Tumor, DLBCL
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
32
Beijing
2022-07-12
Recruiting
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
NCT05315167Advanced Solid Tumor, Advanced Solid Malignancies
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1/2
267
Zhengzhou, Chengdu, Hangzhou, Beijing
2022-05-30
Not yet open
A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.
NCT05320874Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
232
Beijing
2022-04
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
NCT05269316Solid Tumor, Advanced Solid Tumor
Impact Therapeutics, Inc.
Phase 1/2
61
Beijing
2022-02-11
Recruiting
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
NCT05170958Advanced Solid Tumor
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
Beijing, Harbin, Wuhan
2021-09-27
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Recruiting
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
NCT04093466Advanced Solid Tumor
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 1
126
Beijing
2020-04-27
Rows per page Showing 1–63 of 63
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 63 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

48 of the 63 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 63 studies
PhaseStudiesRecruitingShare
Phase 1342854%
Phase 1/2241738.1%
Phase 2426.3%
Phase EARLY_PHASE1111.6%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
BeOne Medicines1010
Cancer Institute and Hospital, Chinese Academy of Medical Sciences33
LaNova Medicines Limited31
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.22
Daiichi Sankyo21
Eli Lilly and Company21
MediLink Therapeutics (Suzhou) Co., Ltd.21
Suzhou Zelgen Biopharmaceuticals Co.,Ltd21
Xuanzhu Biopharmaceutical Co., Ltd.20
Adlai Nortye Biopharma Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.